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INTRODUCTION 
HIV infection has been causing a pandemic all over the world and 
is still considered one of the most dreaded disease to be suffering from 
even in the advent of very effective antireteoviral therapy.  Lots of 
research has been going on in this field. The virus is known to cause 
diseases of almost all systems and can cause protean manifestations that 
can vary from mild to life threatening complications. 
HIV-infected individuals have a higher prevalence of 
cardiovascular disease, which has been demonstrated both using clinical 
end points and utilizing the high resolution ultrasound to assess carotid 
artery intima-media thickness(IMT) were carotid artery intima-media 
thickness has been used a surrogate marker for    atherosclerosis.  
           The government efforts to control  HIV by providing highly active 
anti-retroviral therapy (HAART) free of cost to all individuals will 
control the new incidence of tuberculosis as well. There has been 
tremendous outreach in providing various cART regimens to patients of 
different category according to their needs. WHO also started a campaign 
3 by 5 in 2004 to make HAART available to resource limited areas. 
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           HIV patients have increased risk of cardiovascular disease events. 
HIV-infected individuals may exhibit more rapid IMT progression in the 
carotid artery  compared with uninfected individuals due to inflammatory 
state present in HIV infected .Low cd4 count has been identified as a risk 
factor but data has not been consistent as studies have not confirmed the 
reported associations of low CD4+ T-cell count with clinical or 
subclinical CVD .The aim of the study is to investigate the correlation 
between CD4 count and CAROTID INTIMA MEDIA THICKNESS as a 
marker of atherosclerosis in HIV patients 
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AIMS AND OBJECTIVES 
 
I. To investigate the correlation between CD4 count and CAROTID 
INTIMA MEDIA THICKNESS as a marker of atherosclerosis in 
HIV patients 
II. To study the relationship between Carotid intima media thickness 
and the duration of antiretroviral therapy 
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REVIEW OF LITERATURE 
1. SOURCE OF LITERATURE 
The literature source for review of our study was taken from 
published studies describing the pattern of disease spread, pathogenesis, 
CD4 count and its relation to carotid intima media thickness (CIMT) . 
Priority was given to more recent studies and older studies were used 
when no other data is available. Articles published in English were only 
used. WHO site and Medline were the main electronic data used for the 
review of literature.  
Indian studies were given priority and global scenario was used for 
comparison. Studies about atherosclerosis in HIV were appraised from 
few articles. The aim of selecting the literature review was to fill the gaps 
in knowledge regarding atherosclerosis in HIV. The main limitations 
were the lack of convincing studies from India regarding incidence of 
atherosclerosis in HIV patients and with regards to ART duration. 
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2 .  INTRODUCTION 
HIV or human immunodeficiency virus belongs to the family - 
human retrovirididae and subfamily – lentiviruses. The virus is unique in 
its way because of its ability to convert its RNA genome into DNA to get 
incorporated into host genome by the enzyme reverse transcriptase. The 
Acquired immunodeficiency syndrome (AIDS) was first described in 
United States in 1981 in homosexual men who presented with Kaposi 
sarcoma and Pneumocystis jiroveci. The causative virus was isolated in 
1983. ELISA TEST was developed to detect the antibodies in 1985. Since 
then there has been enormous turnabout of events and expanding 
information and paradigm shift in treatment approaches in HIV patients.1 
Phylogenetic analysis of certain earlier isolates show that HIV 1 
was prevalent even before the AIDS pandemic. HIV 1 the common 
infectious agent is further sub classified into M, N and O. M type causes 
the global burden of HIV.  It is further subdivided into A-D, F-H and K 
subgroups. HIV 2 is commonly found in west Africa. HIV 1 virus has 
supposedly come from chimpanzee and probably gorilla whereas HIV 2 
is believed to be originated from the   mangabeys. The worldwide 
pandemic of AIDS is caused by M group HIV 1 viruses. Other group 
viruses only cause a localized epidemics. 2 
9 
 
   Subtype C is responsible for almost half of the HIV-1 infections  
worldwide and is predominantly found in southern Africa and India . 
Subtype B predominates in North America, western as well as central part 
of Europe, the Caribbean islands, and Latin America.5 
 
3. EPIDEMIOLOGY 
The present global HIV epidemic is quite different from that first 
recognized among a small number of homosexual men as early as the  
1981. The epidemic has reached almost every country all over the world 
and nearly all populations throughout the world. The  spread of the HIV 
pandemic  has been particularly alarming in resource-limited countries, 
especially the sub-Saharan part of  Africa and southeast Asia, but 
continues to threaten other population  in eastern part of the Europe, Latin 
America, and the Caribbean islands.3,4 
10 
 
36.7 million of ad ults and children all over the world were       
diagnosed with HIV/AIDS and 2.1 million people had been  infected 
newly with HIV in the year of 2015. About 1.1 million people died of 
AIDS in the same year. The global prevalence rate was 0.8 percent 
worldwide in patients of age 15 – 50 years . Incidence of new HIV viral  
infections represents a decline of 38 percent in 2015 when compared to 
2001.  
 
Children constitute a majority of persons who are infected and 
about 3.3 million children are HIV positive. Seventy five percent of the 
HIV infected individuals live in AFRICA particularly sub sahara region. 
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The prevalaence rate  varies  according to the region ranging from less 
than 0.1 percent in middle east to 5 percent in African countries. 
HIV has occurred in various countries as cycles and the most 
affected region is sub Saharan Africa . The seroprevalence rate is very 
high in the rank of more than 10 % of the population . Heterosexual  
mode of transmission is most common in Africa.  
Even though overall  prevalence rates of HIV load  in Asia is 
slightly  low, that is approximately 0.6 percent , this still results in a 
substantial burden of disease, as the  region accounts for about half of the 
the world’s population. Of the estimated 5.1 million HIV-infected 
persons living in Asia, nearly half live in India. Approximately 85 percent 
of HIV transmission in India is postulated to be through sexual 
transmission. Barriers to control of the epidemic is due to fact that 
acceptance of condoms is very less and enforcing laws that make 
homosexuality illegal and punishable by imprisonment. MSM prevalence 
rate in India is estimated to be 18 percent which is higher when compared 
to neighbouring countries.6 7 
                  
 
 
12 
 
 
In central asia 1 million people had HIV and The Russian 
federation and Ukraine had majority of the cases. In South America 2 
million had HIV and in that Brazil had highest number of HIV patients. 
But incidence there has reduced to due to successful prevention efforts. In 
north America ,2.5 million people were affected and men who had sex 
with men constituted the majority of the patients. 8 
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 4.TRANSMISSION 
  Four distinct risk groups have been identified in  the category of 
non-occupational exposure to HIV infection, including men who have sex 
with men (MSM), male and female heterosexuals, injection drug users 
(IDUs), and also persons exposed to HIV through other routes of 
transmission like  human bites .9, 10 
Worldwide sexual transmission constitutes the majority of the 
cases occurring due to viral transmission. Anal mucosa being more 
fragile leads on to more infection rates compared to infections in the 
vaginal mucosa. And also to be noted is receptive sex suffer from more 
transmission rates than insertive sex which in turn supports the fact that 
femalehavemuch higher rates of infection than men. The female to male 
transmission rate was 0.04% whereas the male to female transmission 
rate was found to be 0.08% .  
Anal mucosa gets infected by the virus either by direct inoculation 
or by infection of the langerhans cells presnt in mucosa . HIV is 
demonstrated to be present both cell free as well as within mononuclear 
cells. Presense of other sexually transmitted infections also increase the 
rate of viral infection. So treating other STIs in addition reduces 
incidence of acquiring HIV Iinfection12. Circumcision in men is 
protective against acquiring infection because  the foreskin which 
 provides moist environment for microbes 
langerhans cell is got rid of in circumscribed men. Rate of transmission is 
more in early stages of infection and also in advanced stages which 
reinforces the fact that HIV RNA load is directly proportional to rates of 
transmission.11  
Male to female 
prolonged exposure of vagina to seminal secretions as compared to men 
genitalia where the female secretion contact time is less. Oral 
contraceptive pills use increases infection as cervica mucosa is 
vulnerable. Adolescent girls have exposed columnar epithelium in cervix 
which favours infection.
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Transmission through IDU or injection drug users occurs when 
sharing needles, cotton, syringes. They can infect by not only intravenous 
route but also subcutaneous and muscular route as well . The per act risk 
of transmission is about 0.58% 
The risk of transmission is less with other bodily fluids or 
secretions.  In case of saliva it has HIV specific immunoglobulins as well 
as soluble factors in saliva like SLPI (secretory leucocyte protease 
inhibitor) . 
In case of mother to child transmission it can occur during 
antenatal period , labour period ,and breast feeding . in this highest share 
is in lobour period when upto 65 % transmission occurs. The rate of 
transmission is about 30 % in underdeveloped countries . Risk Factors for 
increased transmission includes HLA mismatch , prolonged ruptured 
membranes , chorioamnionitis , episiotomy and other invasive procedures  
In breastfeeding women , mastitis , high viral load , HIV present in 
milk , low CD 4 counts all favor infection of the baby. Early c ART and 
cesarean section  all decreases incidence of infection to child. 
Occupational exposure to health care workers constitutes about 
1000 cases per year . Rates  of transmission for needle injury is 0.3% and 
in case of mucous membrane it is 0.09%. Non intact skin exposure is less 
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compared to mucous membrane . Risk factors for infection include deep 
injury ,prolonged exposure , big bore needle ,large quantity of blood 
,advanced stages of AIDS . Early instituition of PEP (POST –
EXPOSURE PROPHYLAXIS)   has very much reduced infection rates if 
given within 24 hours of exposure . other potential infectious fluids 
include cerebrospinal fluid , semen , vaginal secretions , pleural fluid , 
pericardial fluid , amniotic fluid . 
 
5.VIRUS STRUCTURE 
The virus has a diameter of 100-120 nanometer with a spherical 
morphology. It has a truncated core with a lipid core. The viral core 
contains 2 copies of single stranded RNA, along with the enzymes 
protease, integrase and reverse transcriptase. The viral genome is 9.2 kilo 
base pairs long and contains 3 structural, 2 envelope and 3 genes for 
enzymes. It is a single- stranded and  positive sense RNA. Their ends are 
covered by polyadenylated caps which prevents it from enzyme 
degradation. There is an element called tyrosine RNA which acts as a 
primer of viral RNA  
17 
 
 
HIV-1 virus consists of two copies of non-covalently linked and, 
 positive-sense , unspliced and single-stranded RNA which is surrounded 
by a conical capsid composed of the virus protein  called as p24, which is 
typical of  lentiviruse family . The RNA component is 
9749 nucleotides long and bears a  5’ cap (Gppp), a 3’ poly(A) tail. The 
RNA has many open reading frames (ORFs). Viral structural proteins are 
encoded by long ORFs, whereas smaller ORFs encode regulators of the 
viral life cycle that is attachment, replication, membrane fusion, and 
assembly . 
HIV GENOME 
The Human immunodeficiency virus contains the genes called the 
regulatory genes. These help the virus to produce proteins and help the 
virus from infection and replication. 
 TAT gene –  
 (Tran’s activator of transcription) ie p14 is a regulatory gene 
which is encoded by 2 different exons. It codes for a protein which is 102 
Amino acid long which  acts through TAT  receptor binding which 
activates viral transcription. When it is shed into circulation, there is a 
chance of development of antibody to this protein. 
apoptosis of both CD4 cells which are infected and those which are not 
infected. It can act as a neurotoxin, which is shown in vitro experiments. 
Therefore it enhances RNA pol elongation of viral genome.
REV gene– 
It is another regulator
protein the function 
transport is important for early and late phases of viral replication
18 
It however induces 
y gene which forms an essential accessory 
of which is to transport mRNA. Rev dependent RNA 
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VIF gene – 
Also known as the viral infectivity factor . It produces a 23 kilo 
Dalton protein found in  the cytoplasm. It helps the virus to infect cells 
which contain CD4 receptors. The mechanism of action is less clear. 
Thought to overcome inhibitory effects of APOBEC3 preventing viral 
DNA degradation. The significance of Vif gene is the viruses with no Vif 
gene infect other cells at least 25 times slower than other viruses. 
 
NEF gene –  
Negative factor, produces a 27 kiloDalton protein. It helps in 
downregulation of the receptor expression and enhances infectivity of the 
virus. Nef Phenotypes of the viruses are present but not understood to a 
large extent. 
 
VPU gene –  
Viral protein U, It produces a protein which is 81 amino acids long. 
It is a membrane protein which also encodes envelope and controlled by 
Rev. It helps in release of virus  from plasma membrane of infected cell 
and degrades the  CD4+ cells in the endoplasmic reticulum. 
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VPR gene –  
Viral protein R, produces a protein which is 96 amino acids long 
one more protein 14kDa responsible for G2 phase cell cycle arrest . This  
will indirectly improve  viral replication by increasing transcription from 
LTR. Vpr expression causes breaks in the structure of nuclear lamin, 
which will weaken nuclear envelope and intrudes with DNA synthesis 
thus cause cell cycle arrest prior to mitosis. It also supports infection of 
non-dividing cells, mostly macrophages. Vpr also functions to connect 
the pre-integration complex along with  the cellular nuclear import- 
machinery.  
Structural proteins are encoded by three genes called as gag , pol, 
env . Gag encodes for  the proteins that will form the core including the 
p24; Pol encodes the enzymes responsible for protease that is responsible 
for processing of viral proteins, reverse transcriptase ,and integrase ; and 
Env encodes the envelope proteins. 
  However, HIV-1 is much more complex than other retroviruses , 
especially that of the nonprimates, in that it also contains at least six other 
genes t(rev,tat, vif,nef, vpr, and vpu), which will code for proteins that is 
needed for  the modifying of the host cell to enhance virus growth . LTRs 
or long terminal repeats has the regulatory genes that is involved in gene 
expression .The major difference between HIV 1 and HIV 2 is the fact 
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that HIV 2 does not have vpu gene  and has a  vpx gene not contained in 
HIV 1. 
 
6.HIV REPLICATION CYCLE  
The replication cycle begins when the gp 120 binds via the V1 
region to the CD4 molecule. It is present mainly on the CD4 subset of 
lymphocytes and also on  the surface of  monocytes or macrophages , 
dendritic  or Langerhans cells. After binding  to CD4, gp120 protein 
undergoes a conformational change that cause the binding to one of two 
major co-receptors. CCR5 and CXCR4 are two major co-receptors for 
HIV-1. 
 
Both receptors belong to 7-transmembrane domain G protein–
coupled receptors (GPCR) family, and the use of these receptors by the 
virus for entry into the host cell is an very important determinant for  the 
tropism of the hiv virus. Certain dendritic cells (DCs) will  express a 
variety of C-type lectin receptors on their surface, for example ,DC-SIGN 
which binds with  the HIV gp120 envelope protein, allowing DCs to 
facilitate virus infection to CD4+ T cells. Following binding of the gp120 
to the CD4+ molecule along  with the above mentioned conformational 
change in the viral envelope gp120, fusion with the host plasma cell 
membrane occurs via the newly exposed gp41 . This helps in penetrating 
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the plasma membrane of the target cell and then coiling upon itself to 
bring the viarl particle and target cell together.16 
    
Following fusion of virus and host cell, uncoating of the capsid 
protein shell is started  that facilitates reverse transcription and leads to 
the subsequent formation of the preintegration complex, composed of 
viral RNA, enzymes, and accessory proteins and surrounded by capsid 
proteins . As the preintegration complex transports across cytoplasm 
reverse transcriptase converts RNA to DNA.  
 
When the cell is activated , the viral DNA can enter inside nucleus 
through the nuclear pore and is transported  from the cytoplasm to the 
nucleus, where it is integrated into the host cell genome through the 
action of important enzyme called as integrase . HIV provirus (DNA) 
integrates into the nuclear DNA preferentially within introns rather than 
exons of genes and hotspots within specific region. This provirus may 
remain transcriptionally inactive or it may lead on to varying levels of 
gene expression, up to the level of even active production of virus.14 15 
 
Activation of host cell is needed for transcription of the proviral 
DNA that was previously integrated into host DNA . After transcription 
the mRNA is translated into various structural proteins. Infectious virus 
particle is formed by assembly of various proteins ,enzymes, RNA at the 
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outer  membrane of cells. Budding of virus  through lipid bilayer is when 
the core acquires the external envelope. The protease enzyme causes 
breakdown  of gag pol  precursor to yield mature virus particle. 
    
There are number of host cell factors that help prevent viral 
replication for example, tetherin interferes with virion detachment 
,TRIM5-a and APOBEC3 family of  proteins also inhibits viral 
progression in the cytoplasm. The beauty of HIV virus lies in the fact that 
the virus is able overcome these factors and replicate.14 
    
                  
 
The reverse transcriptase enzyme has no proofreading activity and 
accumulates mutation at a rate of 
24 
104 – 106   and each time it replicates it 
 
 destroys nearly 2 billion CD4 cells per day. The h
six to eight hours approximately
 
 
 
 
25 
alf-life of a HIV
 
 
 virus is 
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7.CLINICAL FEATURES  
                                           
The Human immunodeficiency virus can have variety of 
manifestations, wherin the symtomatology can range from completely 
asymptomatic patients to completely debilitated patients. Patients can be 
asymptomatic without any significant symptoms for ranging from eight to 
ten years. This is because of the long incubation period of HIV.  As HIV 
advances depleting the CD4 cells, the first manifestations may be the 
initial Opportunistic infections. These diseases are not very common in 
any normal or immunocompetent individual. 
 
Human immunodeficiency virus per se can cause severe 
debilitation and death. Opportunistic infections includes both infective 
and cancerous conditions. The better term to use would be opportunistic 
conditions. 15 
 
The infections seen in HIV infection are protean that they include 
an entire spectrum.. They can be classified as bacterial, viral, parasitic 
and fungal. The frequency of opportunistic infections are dependent on 
the geographic conditions. Overall Tuberculosis is the commonest 
opportunistic infections. Other common infections16  
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seen are pneumocystis jirovecii, CNS infections which are common are 
Tuberculoma, tuberculous meningitis and Primary CNS lymphoma. 
Visceral leishmania are common in some areas of Bihar. According to 
degree of immunosuppression clinical phases can be differentiated into 
primary, early, intermediate and advanced HIV infection.17 
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                    Active replication occurs throughout the process of disease 
along with continued immunological deterioration .Except for the rare 
virus controllers the disease will keep on progressing even in the latent 
stages of the disease .17  
 
 
    
Acute HIV infection 
During this phase patients are extremely infectious. This is of no 
clinical value. Patient usually doesn’t come to hospital at this stage as 
there is no significant clinical deterioration. 
           The initial presentation of HIV infection is similar to an ordinary 
viral infection. Fever, skin rash, headache and diarrhea are the most 
common presentations. As soon as viral replication occurs, there is a 
29 
 
drastic fall in CD4 cell count and at the same time the viral load increases 
rapidly and forms a set point.18 
 
 
      
The acute clinical syndrome lasts for 3 to 6 weeks. If at all there is 
a symptomatic seroconversion patient is prone  for accelerated disease 
progression. Severity is more by sexual route of transmission than by 
injection drug users .there is a reversal of the CD4+/CD8+ ratio such that 
CD4+ cells are reduced and the CD8+ cells are increased. 10% of them 
can have a fulminent course. The primary infection is followed a 
prolonged period of clinical latency.18 
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Patients with CD4 count <500 cells/cubic millimeter are 
considered usually more to be vulnerable to autoimmune diseases and 
neurological illness such as diseases like Bell’s palsy, acute inflammatory 
demyelinating polyneuropathy or guillain barre syndrome, chronic 
inflammatory demyelinating polyneuropathy and Bell’s palsy have 
seemed to occur. 
                     
Primary infection lead to acute syndrome in 3 to 6 weeks when 
there is viremia and retrafficking of lymphocytes . After the acute 
syndrome , immune response to HIV occurs in 1 week to 3 months when 
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the plasma viremia is controlled as well as a chronic latent infection is 
established in the lymphoid tissue which subsequently lead to clinical 
latency. 
 
 
      
ASYMPTOMATIC STAGE 
This stage progresses for a median period of about 10 years that is 
from acute infection to the clinically overt immunocompromised 
manifestations. Patients who have very  high levels of HIV RNA levels 
will progress to symptomatic disease very quickly when compared to 
others.  
When the level of RNA copies is less than 50 copies / ml then 
those patients are called as elite non – progressors as they may not have a 
drastic fall in CD4+ counts when compared to the usually delirious 
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progressive course in other patients. The rate of decline of immunological 
status is estimated to be around 50 / microliters per year.18 
SYMPTOMATIC STAGE 
The clinical stage of AIDS is made in patients who are 6 years and 
more and with CD4+ counts less than 200 per microliter and anyone who 
has HIV associated diseases.19  
          This stage is dictated by clinical opportunistic conditions like 
pneumocystis jiroveci , mycobacteria , cytomegalovirus and many other 
organisms that seldom cause diseases in immunocompromised 
individuals. In addition to mortality due to AIDS defining illness that 
accounts for less than 50% of deaths in HIV patients non – AIDS 
defining illnesses like cardiovascular events ,malignancies and liver 
diseases accounts for about 15% each  for the deaths in HIV patients. 
In general, it should be emhasized that a key element in the 
treatment of complications of HIV infection, even if they are primary or 
secondary, is to aim for good control of HIV virus replication through the 
use of antiretroviral therapy and starting primary and secondary 
prophylaxis for opportunistic infections as and when needed. This 
approach has indeed changed the lives of millions of people suffering 
from this disease.20 
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8.LABORATORY DIAGNOSIS 
Testing is taken from a source which is meant for the State 
government. It is offered to all people who approach the centers 
counselling called ICTC. The centers follows the national AIDS program 
algorithm. The first guidelines were given in 1989 for the diagnosis of 
HIV by the Centre of disease Control.  
Blood screening started in march 1985.They also started testing for 
HIV 2 but was not useful for our country. This was started in the year 
1992. The most recent international update regarding this was started in 
the year 2014. The updates include tests for HIV antigens and newer 
antibodies. HIV nucleic acid tests are included specially. This is to 
prevent the people who may be in window period, in an area of high 
prevalence, this is very important as this percentage might contribute to a 
huge amount of people21 
The rationale behind testing for HIV infection is as follows. After 
viral infection occurs , first antigenemia is observed. It is only after 3 to 8 
weeks that patient will start developing antibodies. Antibodies of IgM 
and IgG are produced subsequently. The period before the production of 
antibody where only the antigen persists is called Window period. The 
first antigens to rise are the protein products of p55 and p24 that are 
actually products of the gag gene. P24 levels continue to rise along with 
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concomitant progression of the disease to AIDS. Antibodies will however 
persist throughout infection. 
 The  diagnostic ability of tests have improved so much such that 
detection of window period has reduced from 22 days for antibody tesing 
to 16 days for p24 antigen testing to 12 days with nucleic acid testing 
(NAT).  
 The standard screening tests include enzyme immunoassay (EIA) 
with a sensitivity of 99.5%. the fourth generation EIA combine combine 
antibodies detection along with p 24 antigen detection . The tests are said 
to be either positive or indeterminate or negative. False positive results 
occur in pregnancy ,blood transfusions previously, influenza vaccination, 
acute viral infection ,hepatic disease ,transplantation. 22              
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Those who test positive are to undergo a confirmatory testing 
whereby Western blot is widely accepted. When antibodies to all the gene 
products namely gag , pol, env is all present it is a conclusive test then . 
The FDA approved positive test for Western blot is if two of the 
following three antibodies to gp41, p24 ,gp120/160 is all present. If at all 
the test turns out to be indeterminate the test is repeated after a month. 
Also other tests like HIV-RNA PCR  or p24 capture assay can be done. 
If a person tests positive for enzyme immunoassay that is done 
twice and turned out to be positive a third confirmatory test like western 
blot is done to confirm the diagnosis. 22 
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Next step if the western blot test turnss negative  , HIV -2 is tested 
for. If the test is indeterminate repeat the test within 4 to 6 weeks. There 
are certain rapid tests like oraquick rapid HIV 1 antibody test and home-
access HIV-1 test system. These can provide results in 1 -  60 min. It has 
a sensitivity and specificity of 99% 
The p24 capture assay is very useful to detect acute HIV syndrome 
because of the fact that lots of antigen is present prior to immunological 
development of antibodies. The fourth generation assays that detect both 
antigen and antibody have replaced the p24 capture assay. Four assays are 
available for this of which RT – PCR Is well accepted test. The RNA 
detection tests have a sensitivity of 50 – 1800 copies per milliliter of 
blood. As they tests are highly sensitive some false positive results do 
occur. For this reason it’s the enzyme immunoassay and western blot that  
is still the gold standard.22 
RT PCR is used for finding out drug resistance, prognosis, in 
patints where serology testing is not proper (like in hypogamma 
globulinemia and advanced AIDS) and also only when the standard 
serological testing has not produced a confirmed result. 
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9.CD4 COUNT 
The core brunt of the HIV infection and the primary lesion will be 
involving the CD4+ CELLS. Both a qualitative as well as a quantitative 
defect occurs proving the fct that these group of cells are very important 
in immune regulation. Even when the count is normal there can be a 
qualitative dysfunction of these cells that can demonstrated. In the GALT 
the CD4+ TH1 cells are affected first which are the cells that maintain the 
mucosal defence mechanism and these cells do not recover even after 
prolonged antiretroviral therapy. In the lymph nodes , TFH cells are 
infected but in contrast these cells will increase in number more so in 
patients who are viremic. The CD4+ cells that produce IL – 2 are 
depleted much earlier than compared the cells which will produce IFN . 
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The CD4+cells also expree co stimulatory molecules such as CD28 which 
is important for early activation. But in HIV infected cells this is not 
expressed instead late markers of activation like HLA-DR,CD45 and 
CD38 are expressed.23 
The T- regulatory cells or the t-regs is important in regulating the 
aberrant immune activation that facilitates the viral infection. The CD4 is 
important for the fact that it is by this receptor the gp120 binds along with 
co stimulatory molecules CXCR4 and CCR5 which facilitates in virus 
entry and replication.  
The CD4 cell count becomes resistant to antiretroviral therapy after 
a certain stage ,that is the counts will not rise even after therapy . This is 
because of the destruction of the thymic precursor cells and also 
destruption the the lymph node micro environment. It is also found that 
IL -7 is increased in level because the respective receptor for it, that is, 
CD127 is damaged leading to reduced use of the cytokine and further 
increase in its levels. 
 The CD4+ T cell count is a  laboratory test that is widely accepted 
as the reliable indicator of the immediate status of immunological 
competence of the patient with HIV disease. The CD4+ count  can be 
determined either directly or it can be calculated as the product of  
percentage of CD4+ T cells  and the total lymphocyte count . The CD4 
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cells percentage can be counted by flow cytometry and the total 
lymphocyte count can be determined by the white blood cell count  
multiplied by the differential percentage of the lymphocytes.23 
The CD4+ count  derived has been proven to correlate very well 
with the level of immunological competence that it is used for monitoring 
the therapy effects as well. Patients with CD4+  cell count 
<200/microlitre  are at high risk to acquire Pneumocystis jiroveci and  
patients with CD4+ cell count <50/microlitre  can  develop infections due 
to  Cytomegalovirus , Mycobacterium avium complex, Toxoplasma 
gondii. If  the CD4 cell count is <200/microliter, patients should be 
started  on for P. jiroveci prophylaxis, and if the CD4 count is  
<50/microliter , prophylaxis for MAC is to be given. It is always  prudent 
to take two definite values prior to any significant changes in patient 
management based on CD4+ T cell count alone.  
Patients with HIV infection should have CD4+ count performed at 
time of diagnosing and then after every three to six months thereafter. 
More frequent measurements of the values should be made if at all  a 
declining trend is noted. For patients who have been on antiretroviral 
therapy for a minimum of 2 years and those with  HIV RNA levels 
persistently  <50 copies/  microliter , the monitoring of the CD4 count can  
be optional. 24 
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There are a number of clinical situations in which the CD4 cell 
count may be falsely increased or decreased . Patients with both HTLV 
and HIV co-infection may have a falsely elevated CD4+  cell counts that 
can give a false picture of good  immunological status eve when the 
patient is deteriorating. In patients with hypersplenism or those who have 
had previous history of splenectomy, and in patients taking drugs that 
suppress the bone marrow cells such as IFN-α, the CD4+ cell percentage 
may be a more helpful and prudent  marker of immune function than the 
CD4+ T cell count. A CD4+ T cell percentage of fifteen  is  equivalent to 
a CD4+ T cell count of 200/ microlitre .24 
 
10. CAROTID INTIMA MEDIA THICKNESS 
The first structural change that can be detected in atherosclerosis is 
an increase in  intima media thickness. Intima-media thickness is an 
important atherosclerotic risk marker. There can be smooth muscle cells 
hyperplasia and fibrocellular hypertrophy leading to medial hypertrophy 
and compensatory arterial remodeling. Therefore this process may be an 
adaptive response to changes in flow, wall tension, or lumen 
diameter. The uniform thickening progresses in straighter arterial 
segment of vessels as the patient ages and all known atherosclerotic risk 
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factors accelerate this process. Therefore IMT is an important 
atherosclerotic risk marker 25 
IMT is a marker of subclinical atherosclerosis  that is 
asymptomatic organ damage and should be evaluated in every 
asymptomatic adult or hypertensive patient at moderate risk for 
cardiovascular disease. Intima-media thickness values of more than 0.9 
mm (ESC- European Society of Cardiology) or over the seventy fifth 
percentile (ASE- American Society of Echocardiography) should be 
considered abnormal. Carotid artery ultrasound scan is the method of 
choice and results are quite reliable provided certain standards are 
followed.26 
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Examination of the carotid wall gives every clinician an 
opportunity to evaluate for the subclinical changes in wall structure 
that precede as well as  predict future cardiovascular clinical events. 
B-mode ultra sonography is a noninvasive, reproducible, sensitive, 
safe, easily performed, relatively inexpensive and widely available 
method for detection of early stages of atherosclerosis and is 
accepted as one of the best methods for evaluation of arterial wall 
structure.  
IMT is defined as a double-line pattern visualised by echo 2D 
on both walls of the common carotid artery (CCA) in a longitudinal 
view. The two parallel lines (leading edges of two anatomical 
boundaries) form it: lumen-intima and media-adventitia interfaces .25 
Which IMT values should be considered as abnormal is 
controversy. The relationship of IMT with cardiovascular risk is 
continuous and determining a threshold IMT value would be not 
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correct as it is a dichotomy. Nevertheless, it should be noted that in 
the  ESH / ESC hypertension guidelines , carotid IMT > 0.9 mm has 
been said as a marker of asymptomatic organ damage, although it 
has been proven that in middle-aged and elderly patients the 
threshold values indicating high cardiovascular risk are higher   
   The American Society of Echography (ASE) Task force 
recommends that IMT ≥ seventh fifth percentile is considered high 
and indicative of increased cardiovascular risk. Values from the 
twenty five  to seventy fifth percentile are considered average and 
indicative of unchanged cardiovascular risk. Values ≤ twenty fifth 
percentile are considered low and indicate lower than the expected 
cardiovascular risk.  
High-resolution B-mode system (B-mode imaging   is 
preferred over M-mode ), equipped with a linear array   transducer 
>7 MHz with minimal compression and footprint of at least 3 cm. 
Use of a zoom function is discouraged . IMT measurement is done at 
a distance of at least 5 mm below the distal end of CCA  , along a 
segment of the artery free of atherosclerotic plaque with clearly 
defined lumen-intima and media-adventitia interface .10-mm-in-
44 
 
length straight arterial segment is required and the far wall of the 
common carotid artery is preferred.26 
 The following table gives the IMT values – median (P50), 
25th and 75th percentile (P) IMT values for men and women at 
different age categories of which values more than P75 are 
significant. 
 P25 P50 P75 
MEN      <30 0.39 0.43 0.48 
MEN      31-40 0.42 0.46 0.50 
MEN      41-50 0.46 0.50 0.57 
MEN      >50 0.46 0.52 0.62 
WOMEN <30 0.39 0.40 0.43 
WOMEN 31-40 0.42 0.45 0.49 
WOMEN 41-50 0.44 0.48 0.53 
WOMEN >50 0.50 0.54 0.59 
 
11.CARDIOVASULAR EFFECTS OF HIV 
HIV infection per se may  promote atherosclerosis either by 
activating the vascular endothelium directly, or by systemic cytokine 
release by the virus indirectly . Higher rates of sub-clinical 
atherosclerosis are seen in HIV-1-infected patients, and, these can 
also be due to the classical cardiovascular risk factors and due to the 
side effect profile of cART 30.Recent studies have suggested that 
viral factors, in addition to the traditional cardiovascular risk factors, 
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have independent negative effects, possibly by causing abnormalities 
in lipid levels, monocyte attraction and migration into the intima of 
vessels and a state of chronic inflammation31 . Effects of vascular 
alterations in patients with HIV can be secondary to direct effects of 
the HIV virus on vascular function, including direct alteration in 
endothelial function, inflammation, and modification of aortic wall 
vascular smooth muscle cell behaviour and extracellular matrix 
composition changes.32 
Studies have shown that HIV patients have elevated levels of 
hsCRP , IL-6, TNF- alpha. Studies also suggest that chronic 
inflammation in HIV infection may partially underlie the reduced 
vascular function and premature atherosclerosis33 
Endothelial dysfunction is a common feature of atherosclerosis 
.There is a increasing evidence to suggest HIV itself may have 
deleterious effects on endothelial function. Patients with HIV have 
been shown to have reduced vascular reactivity  similar to patients 
type 2 diabetes mellitus. Increased secretion of monocyte 
chemoattractant protein 1 as well as increased expression of  
adhesion molecules like vascular cell adhesion molecule-1 (VCAM-
1)  , intercellular adhesion molecule 1 and E-selectin is present 34. 
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Vascular endothelium from patients with HIV have increased 
monocyte adherence and its migration into the intima during plaque 
development. In addition, several HIV proteins, notably Tat and 
gp120 are causing endothelial cell activation and increased 
expression of the cell adhesion molecules . 35 
This along with the fact that HIV infection affects lipid 
processing and is associated with lower HDL cholesterol, lower 
apolipoprotein B levels and smaller LDL cholesterol particles, this 
environment provides an atherogenic milieu. Although few studies 
have shown that ART may reduce endothelial activation, it does not 
appear to completely ameliorate the effects of HIV infection, 
suggesting that even during complete virological suppression, 
endothelial dysfunction continues to promote atherosclerosis in HIV 
patients.36 
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MATERIALS AND METHODS 
SETTINGS 
The study was conducted in the Institute of Internal medicine and 
ART centre at Madras Medical College and Rajiv Gandhi Government 
General Hospital. 
ETHICAL COMMITTEE APPROVAL 
The study was approved by the Institutional Ethics Committee of 
Madras Medical College, Chennai  
STUDY DURATION 
This study was done for a duration for a period of six months. 
STUDY POPULATION 
Patients attending ART center OPD and  medical wards with HIV 
infection.  
TYPE OF STUDY 
Observational study of 100 patients   
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SAMPLE SIZE 
100 patients recruited from Institute of Internal medicine and 
Antiretroviral center from Rajiv Gandhi Government General Hospital 
Chennai. 
INCLUSION CRITERIA 
Patients who are HIV infected as evidenced by ELISA and western 
blot Reactivity 
EXCLUSION CRITERIA 
1. Patients with history of diabetes mellitus 
2. Patients with history of hypertension 
3. Patients with coronary artery disease 
4. Patients with chronic kidney disease 
5. Patients with history of smoking 
 
50 
 
DATA COLLECTION AND METHODS  
We examined 100 patients recruited from Institute of Internal 
Medicine, and Anti-retroviral center at Madras Medical College and 
Rajiv Gandhi Government General Hospital. Patients were selected for 
clinical study as per inclusion/exclusion criteria and demographic data , 
past medical history , ART drug history ,duration of illness was collected 
from patients .CD4 T cell count is measured. Carotid artery intima media 
thickness is measured using B-mode ultrasound . Informed consent was 
obtained from each patient and relatives in necessary cases. They were 
given a questionnaire and were subjected to thorough clinical 
examination. Patients were asked to take routine blood investigations like 
renal function tests, liver function tests, CD4 cell count. All the data was 
entered in the proforma (enclosed). Data was analyzed using Excel data 
analysis software and p value was calculated using paired T test 
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STASTISTICS 
AGE WISE DISTRIBUTION OF CIMT 
 
 
 CIMTMEAN 
Mean Percentile 25 MedianP
50 
Percentile 75 
age_group 
<30 SEX 
Male .38 .20 .30 .60 
Female .41 .35 .43 .48 
31-40 SEX 
Male .39 .35 .35 .45 
Female .43 .30 .40 .50 
41-50 SEX Male .47 .40 .45 .55 
Female .42 .30 .40 .50 
Above 50 SEX Male .61 .38 .48 .90 
Female .42 .30 .35 .50 
 
                        
The above table shows the shows that the mean CIMT was more in 
females in age groups <30 and 31-40 and was more in men in 41-50 and 
>50 age groups. The distribution is similar upto p50 and there is 
increased values in CIMT for men above p75 except in the 31 – 40  
 
 
 
 
 
 
 
  
                                 
 
 
Valid 
<= Significant value
Above significant
 
 
 
The pie chart shows that 47 percent of them had significant values
of CIMT  at p25 
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      PERCENTILE 25(P25) 
Frequency 
 53 
 47 
Total 100 
P25
Percent 
53.0 
47.0 
100.0 
 
 
<= Significant value
Above significant
  
 
                               
 
 
 
Valid 
<= Significant value
Above significant
 
 
 
  
 
The pie chart shows that 33 percent of them had significant values 
of CIMT at p50 
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 PERCENTILE 50 (P50) 
Frequency 
 67 
 33 
Total 100 
P50
Percent 
67.0 
33.0 
100.0 
 
<= Significant value
Above significant
  
                                       
                                              
 
   
 
Valid 
<= Significant value
Above significant
 
 
 
The pie chart shows that 34 percent of them had significant values 
of CIMT at p75 
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   PERCENTILE (P75) 
Frequency 
 66 
 34 
Total 100 
 
P75
Percent 
66.0 
34.0 
100.0 
 
<= Significant value
Above significant
                                   
 
Valid 
 
 
 
 
The x axis shows age groups in ranges and y axis has percentage in 
each 
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 AGE GROUP DISTRIBUTION 
Age Frequency Percent
<30 11 11.0
31-40 34 34.0
41-50 38 38.0
Above 50 17 17.0
Total 100 100.0
 
31-40 41-50 Above 50
34%
38%
17%
AGE GROUP
 
 
 
 
 
 
 
<30
31-40
41-50
Above 50
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CROSSTAB SHOWING THE SIGNIFICANT CIMT VALUES 
ABOVE P25  DISTRIBUTED BY AGE GROUPS 
Crosstab 
 
p25 
Total <= Significant 
value 
Above 
significant 
age_group 
<30 
Count 1 10 11 
% within 
p25 1.9% 21.3% 11.0% 
31-40 
Count 20 14 34 
% within 
p25 37.7% 29.8% 34.0% 
41-50 
Count 23 15 38 
% within 
p25 43.4% 31.9% 38.0% 
Above 50 
Count 9 8 17 
% within 
p25 17.0% 17.0% 17.0% 
Total 
Count 53 47 100 
% within 
p25 100.0% 100.0% 100.0% 
Pearson Chi-Square =9.841*  p=0.020  
 
  
 
The above graph shows that the CIMT values at p25 distributed to 
age groups was significant , p 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
<30
2%
21%
58 
=0.020 
31-40 41-50 Above 50
38%
43%
17%
30%
32%
17%
 
 
<= Significant value
Above significant
 CROSSTAB SHOWING THE SIGNIFICANT CIMT VALUES 
ABOVE P50  DISTRIBUTED BY AGE GROUPS
                                                                   
 
age_group 
<30 
31-40 
41-50 
Above 50
Total 
Pearson Chi-Square =0.187  p=0.980
 
 
The above graph shows that the CIMT values at p50 distributed to 
age groups was not significant , p =0.980
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Crosstab 
p50 
<= Significant 
value 
Above 
significant
Count 7 4 
% within p50 10.4% 12.1%
Count 23 11 
% within p50 34.3% 33.3%
Count 25 13 
% within p50 37.3% 39.4%
 
Count 12 5 
% within p50 17.9% 15.2%
Count 67 33 
% within p50 100.0% 100.0%
 
 
31-40 41-50 Above 50
34%
37%
18%
33%
40%
15%
 
Total 
 
11 
 11.0% 
34 
 34.0% 
38 
 38.0% 
17 
 17.0% 
100 
 100.0% 
 
 
<= Significant value
Above significant
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CROSSTAB SHOWING THE SIGNIFICANT CIMT VALUES 
ABOVE P75 DISTRIBUTED BY AGE GRUOPS 
 
Crosstab 
 p75 Total 
<= 
Significant 
value 
Above 
significant 
age_group 
<30 
Count 6 5 11 
% within 
p75 
9.1% 14.7% 11.0% 
31-40 
Count 26 8 34 
% within 
p75 
39.4% 23.5% 34.0% 
41-50 
Count 28 10 38 
% within 
p75 
42.4% 29.4% 38.0% 
Above 50 
Count 6 11 17 
% within 
p75 
9.1% 32.4% 17.0% 
Total 
Count 66 34 100 
% within 
p75 
100.0% 100.0% 100.0% 
Pearson Chi-Square =10.447*  p=0.015 
  
 
 
The above graph shows that the CIMT values at p75 distributed to 
age groups was significant , p =0.015. The CIMT was more <30,
groups. 
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Valid 
 
 
 
Males constituted 54 percent and females 46 percent 
cases 
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   SEX DISTRIBUTION 
Frequency Percent
Male 54 54.0
Female 46 46.0
Total 100 100.0
 
SEX
 
 
 
 
 
of the total 
MALE 
FEMALE
 CROSSTAB SHOWINGTHE 
ABOVE P25 DISTRIBUTED FOR THE SEXES
 
 
SEX 
Male 
Female 
Total 
    Pearson Chi-Square =0.424  p=0.515
  
 
 
The above graph shows that the CIMT values at p25 distributed for 
sexes was not significant , p =0.515
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SIGNIFICANT CIMT VALUES 
Crosstab 
p25 
<= Significant 
value 
Above 
significant
Count 27 27 
% within p25 50.9% 57.4% 
Count 26 20 
% within p25 49.1% 42.6% 
Count 53 47 
% within p25 100.0% 100.0%
 
 
Female
49%
57%
43%
 
Total 
 
54 
54.0% 
46 
46.0% 
100 
 100.0% 
 
 
<= Significant value
Above significant
 CROSSTAB SHOWINGTHE SIGNIFICANT CIMT VALUES 
ABOVE P50 
 
 
 
SEX 
Male 
% within p50
Female 
% within p50
Total 
% within p50
Pearson Chi-Square =0.603  p=0.437
 
The above graph shows that the CIMT values at p50 distributed for 
the sexes was not significant , p =0.437
0%
10%
20%
30%
40%
50%
60%
Male
57%
64 
DISTRIBUTED FOR THE SEXES
Crosstab 
p50 
<= Significant 
value 
Above 
significant 
Count 38 16 
 56.7% 48.5% 
Count 29 17 
 43.3% 51.5% 
Count 67 33 
 100.0% 100.0% 
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 CROSSTAB SHOWINGTHE SIGNIFICANT CIMT VALUES 
ABOVE P75 DISTRIBUTED FOR THE SEXES
 
 
SEX 
Male 
Count
% within 
p75
Female 
Count
% within 
p75
Total 
Count
% within 
p75
Pearson Chi-Square =7.257*  p=0.007
 
 
The above graph shows that the CIMT values at p75 distributed for 
the sexes was significant , p =0.007 indicating that females had more 
significant increase in CIMT than males  above the significant values 
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 ART DURATION YEARWISE 
 
     
 
Valid 
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00
Total
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Frequency 
 9 
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 9 
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 1 
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 ART DURATION YEAR RANGE DISTRIBUTION
 
 
 
Valid 
upto 3 years
6 
 
 
 
 
 
 
44%
67 
Frequency 
 40 
4- 6 years 44 
- 10 years 16 
Total 100 
 
40%
16%
ART DURATION
 
Percent 
40.0 
44.0 
16.0 
100.0 
 
upto 3 years
4- 6 years
6 - 10 years
 CROSSTAB SHOWING THE SIGNIFICANT CIMT VALUES 
ABOVE P25 COMPARED TO ART DURATION
 
art 
upto 3 years 
4- 6 years 
6 - 10 years 
Total 
Pearson Chi-Square =5.510 p=0.064
 
The above graph shows that the CIMT values at p25 compared to 
ART duration was not significant , p =0.064
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Count 26 14 
% within p25 49.1% 29.8%
Count 22 22 
% within p25 41.5% 46.8%
Count 5 11 
% within p25 9.4% 23.4%
Count 53 47 
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 CROSSTAB SHOWING THE SIGNIFICANT CIMT VALUES 
ABOVE P50 COMPARED TO ART DURATION
 
 
art 
upto 3 years 
4- 6 years 
6 - 10 years 
Total 
Pearson Chi-Square =5.097  p=0.078
 
The above graph shows that the CIMT values at p50 compared to 
ART duration was not significant , p =0.078
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 CROSSTAB SHOWING THE SIGNIFICANT CIMT VALUES 
ABOVE P75 COMPARED TO ART DURATION
 
 
art 
upto 3 years 
4- 6 years 
6 - 10 years 
Total 
Pearson Chi-Square =11.061*  p=0.004
 
 
The above graph shows that the CIMT values at p75 compared to 
ART duration was  significant , p =0.004 indicating that patients on ART 
for 6-10 years had more 
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 GROUP  STATISTICS SHOWING MEAN CD4 COUNT FOR P25 
 
 
Group Statistics 
 p25 N Mean Std. 
Deviation 
Std. Error 
Mean 
CD4_COUNT 
<= Significant 
value 53 587.7925 221.27127 30.39395 
Above significant 47 344.9149 200.88801 29.30253 
t value =5.719 * p<0.001 
 
 
 
 
 
 The above graph shows that the significant mean cd4 count was 
344 for patients with cimt above p25 ,p <0.001 
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GROUP STATISTICS SHOWING MEAN CD4 COUNT FOR P50 
 
Group Statistics 
 
p50 N Mean Std. Deviation Std. Error Mean 
CD4_COUNT 
<= Significant value 67 547.6119 233.39010 28.51314 
Above significant 33 323.4545 190.86499 33.22533 
t value =4.782 * p<0.001 
 
 
  
 
The above graph shows that the significant mean cd4 count was 
323 for patients with cimt above p50 ,p <0.001 
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GROUP STATISTICS SHOWING MEAN CD4 COUNT FOR P75 
 
Group Statistics 
 p75 N Mean Std. Deviation Std. Error Mean 
CD4_COUNT 
<= Significant value 66 559.6667 228.76507 28.15903 
Above significant 34 306.6471 176.97079 30.35024 
t value =5.634 * p<0.001 
 
 
 
 
 
The above graph shows that the significant mean cd4 count was 
306 for patients with cimt above p75 ,p <0.001 
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CORRELATIONS OF CD4 COUNT WITH CIMT AND ART 
DURATION 
 
Correlations 
 CIMTMEAN ART DURATION 
CD4_COUNT 
Pearson Correlation -.509** -.335** 
Sig. (2-tailed) .000 .001 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
 
 
The above graphs show there is a negative correlation between 
CD4 count and CIMT values as well as between CD4  count and ART 
duration.  
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RESULTS 
                                    
The results obtained were compared to age adjusted normal values 
for CIMT . It was found that the following number of patients had 
significant values according to percentiles. At p25 the number of patients 
was 47 ,  p50 the number of patients was 33 , p75 the number of patients 
was 34. 
 
AGE DISTRIBUTION 
In our present study, the distribution of patients as follows : below 
30 years was 11 , 31-40 years was 34 , 41-50 years was 38 , above 50 
years was 17. At p75 significant values of CIMT was noted for age 
adjusted values and it was found that values are more in age groups 
below 30 years and above 50 years . 
SEX DISTRIBUTION 
54 % of the study population were males and 46 % were females. 
The CIMT values at p75 distributed for the sexes was significant , p 
=0.007 indicating that females had more significant increase in CIMT 
than males  above the significant values  
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ART DURATION 
The graphs show that the CIMT values at p75 compared to ART 
duration was  significant at p75 , p =0.004 indicating that patients on 
ART for 6-10 years had more CIMT values compared to other age 
groups. 
                           
 MEAN CD4   
  The mean CD4 counts was found to be in decreasing trend with 
increasing percentile of CIMT . The count was 344, 323, 306  for p25 , 
p50 , p75 respectively and was significant with p value < 0.001.         
                          
CORRELATIONS                
The crux was to find out if there  is a correlation between CD4 
count and CIMT and it was found to have a negative correlation (the 
Correlation is significant at the 0.01 level (2-tailed).  meaning that the 
CIMT values were increasing in trend when there was a fall in mean CD4 
count. 
There was also a negative correlation between CIMT values and 
ART duration indicating that CIMT was more for patients who are on 
prolonged ART. 
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DISCUSSION 
The aim of the study was to investigate if the degree of immune 
suppression as indicated by a reliable marker , the CD4 count ,  was 
correlating with atherosclerosis which in turn can be assessed by CIMT 
(carotid intima media thickness).CIMT is considered a surrogate marker 
for atherosclerosis. 
Among HIV patients, low CD4+ T-cell count has been identified as 
a risk factor for atherosclerosis. However, the data has not been 
consistent as few studies have not confirmed the reported associations 
low CD4+ T-cell count with clinical or subclinical cardiovascular disease 
(CVD). Several potential mechanisms have been described that can 
explain HIV and its treatment with increased risk of vascular disease. 
Individuals with untreated Human retroviral  infection have reduced 
levels of high-density lipoprotein cholesterol (HDL-C) and increased 
levels of triglycerides, which happen to be risk factors for vascular 
disease. Initiatng antiretroviral therapy will normalize the lipid 
parameters (total cholesterol, LDL-C and triglycerides, but not HDL-C) . 
Protease inhibitors (PI), can  have adverse effects on LDL-Cholesterol 
and triglyceride levels, blood pressure, and  diabetes . The study did not 
include patients taking protease inhibitors .Circulating markers of 
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inflammation such CRP may be increased among  patients with HIV , 
especially when  AIDS occurs. 
Values of CIMT was noted for age adjusted values and it was 
found that values are more in age groups below 30 years and above 50 
years . There are not sufficient studies in this regard for age adjusted 
atherosclerosis risk distribution although multiple confounding factors 
can contribute to these results , patients with any known co morbid 
conditions predisposing to atherosclerosis were effectively screened and 
excluded from the study 
It was also found that female had more incidence of higher CIMT 
values than men. Insufficient studies are present in this parameter 
although in one study women had increased prevalence of mean CIMT, 
compared with healthy controls and histology was similar to women with 
systemic lupus erythematosus and rheumatoid arthritis . Histologic 
studies of carotid plaques in HIV-infected individuals show extensive 
inflammatory infiltration of the vascular wall, more similar to arteritis 
than to classical atheroma, which is further evidence of an atypical 
vascular disease phenotype  in the HIV-infected patients consistent with 
the above findings. 
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In this study it was also found that the CIMT was more in patients 
on prolonged antiretroviral therapy which can indicate the disease activity 
has overtaken the effects of the drug therapy leading on to accelerated 
atherosclerosis along with a decreased CD4 count  
           Previous studies have revealed that the prevalence of carotid 
lesions was higher in HIV patients who had a CD4+ T-cell count 
measurement below 200 cells/mm3 when compared to HIV uninfected 
persons , consistent with evidence that low CD4+ T-cell count may 
increase risk of CVD in HIV populations. The main results from SMART 
(Strategies for Management of Antiretroviral Therapy) trial appear to be 
consistent with the current finding that immunosuppression ( low CD4 
count) was associated with increased atherosclerosis. The association 
between low CD4+ T-cell count may plausibly be explained by chronic 
inflammation or specific pathogen exposures in immunosuppressed HIV 
patients. 
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LIMITATIONS OF THE STUDY 
 
1. The data was collected from a single center. 
2. The sample size is small for HIV infected population. 
3. Potential for Bias and hence inaccuracy. 
4. Factors have to be reduced more 
5. This was a study of subclinical atherosclerosis measures   rather   
    than hard cardiovascular disease events.                                             
 
Large multi-centric studies in future prospective studies are needed 
to fully ascertain the accuracy of the above findings. 
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CONCLUSION 
                   
It was found that HIV-infected patients with a low CD4+ T-cell 
count had a significantly increased prevalence of subclinical carotid 
artery lesions in the form of increased carotid intima media thickness 
(CIMT) indicating that there is increased atherosclerosis in these 
immunocompromised group of patients. 
It was also found that CIMT was increased in older age group 
compared to younger age group HIV infected. HIV infected females had 
increased CIMT values than men which can indicate  a inflammatory 
pathology. Prolonged duration of ART was associated with increased 
values of CIMT. 
           These findings emphasize that the association of antiretroviral 
therapy use and other HIV related variables with atherosclerosis is in 
need of further study. Further studies are needed in this regard to know 
the exact pathogenesis of atherosclerosis in HIV patients as well as to 
know the effectiveness of the antiretroviral therapy in controlling 
atherosclerosis. More research is needed for developing newer drug 
therapy for atherosclerosis in HIV as well as to evaluate the effectiveness 
of current lipid lowering agents in treatment of the HIV infected patients. 
Prospective studies to reduce chronic inflammation beyond HAART are 
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required to investigate whether or not this improves vascular 
inflammation and function and ultimately reduces atherosclerotic risk in 
patients with HIV     
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ANNEXURES 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
HIV  - Human Immunodeficiency Virus 
AIDS  - Acquired Immunodeficiency Deficiency Syndrome 
ART  - Antiretroviral Therapy   
WHO  - World Health Organization  
CD   - Cluster of Differentiation 
TNF   -  Tumor Necrosis Factor 
NK   - Natural Killer Cells  
NOS  - Nitric Oxide Synthase 
ELISA - Enzyme Linked Immuno Sorbant Assay 
LAC  - Link ART Center 
CIMT -         Carotid intima media thickness 
TNF  -         Tumor necrosis factor 
NAT  -         Nucleic acid testing  
 
 
 
         
 
                             
 
PROFORMA 
 
NAME OF THE PATIENT : 
AGE / SEX    : 
IP/OP NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
 
CONTACT NUMBER  : 
PAST HISTORY   :      Diabetes mellitus: 
            Systemic hypertension: 
            Chronic Kidney Disease: 
                                                     Coronary artery disease: 
TREATMENT HISTORY       : 
 
PERSONAL HISTORY          :       Smoking :    
                                                     Alcohol: 
 
GENERAL EXAMINATION  
Pallor:      Icterus:      Cyanosis:      Clubbing:       
Lymphadenopathy:      Odema: 
 
External markers of  HIV : 
 
VITALS : Pulse Rate:          BP:          Respiratory rate:                
Temperature: 
 
SYSTEMIC EXAMINATION 
 
CARDIOVASCULAR SYSTEM   : 
 
RESPIRATORY SYSTEM       : 
 
ABDOMEN               : 
 
CENTRAL NERVOUS SYSTEM : 
 
 
CIMT  by ultrasound : 
  
CD4 cell count(s) : 
 
Other investigations : 
Hemogram:                                         Renal Function Test: 
Liver Function Test:                            
 
 
                        
CERTIFICATE OF APPROVAL 
 
 
             TURNITIN PLAGIARISM SCREENSHOT 
 
 
 
 
                     
  
TURNITIN PLAGIARISM RECEIPT 
 
 
 
 
 
 
  
INFORMATION SHEET 
 
        We are conducting a study on  “ CORRELATION OF CD4 COUNT WITH 
CAROTID INTIMA MEDIA THICKNESS IN HIV PATIENTS” among patients 
attending Rajiv Gandhi Government General Hospital, Chennai Chennai and for that 
your co-operation to undergo ultrasound neck and your blood sample may be valuable 
to us. 
         The purpose of this study is to investigate “ correlation between CD4 count and 
CAROTID INTIMA MEDIA THICKNESS as a marker of atherosclerosis in HIV 
patients” 
 
We are selecting certain cases and if you are found eligible, we may be using 
clinical profile, lab test reports and radiological reports for study purposes which does 
not affect your final report or management. 
 
The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, no 
personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result in 
any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 Signature of Investigator    Signature /left thumb fingerprint of  
      Participant 
 
Date : 
Place :
 
  
ஆராᾼᾲசி தகவ᾿ தா῀ 
ெசᾹைன இராஜிῂ காᾸதி அரᾆ ெபாᾐ மᾞᾷᾐவமைனயி᾿ பιறிய ஒᾞ ஆராᾼᾲசி 
நைடெபιᾠ வᾞகிறᾐ. 
எᾲ.ஐ.வி ேநாயினா᾿ பாதிᾰகᾺப᾵ேடாாிᾹ இரᾷத நாளᾱகளி᾿ ஏιபᾌΆ 
அைடᾺபிιᾁΆ ெவ῀ைள இரᾷத அᾎᾰகᾦᾰᾁΆ இைடேய உ῀ள ெதாட᾽பிைன அறிவேத 
இᾸத ஆராᾼᾲசியிᾹ ேநாᾰகமாᾁΆ. 
அதιᾁ ெவ῀ைள இரᾷத அᾎᾰகளிᾹ எᾶணிᾰைக மιᾠΆ கᾨᾷᾐ பᾁதி ῄேகᾹ 
அவசியΆ அதιᾁ தᾱக῀ ஒᾷᾐைழᾺᾗ ேதைவ   
நீᾱகᾦΆ இᾸத ஆராᾼᾲசியி᾿ பᾱேகιக நாᾱக῀ விᾞΆᾗகிேறாΆ. ᾙᾊᾫகைள அ᾿லᾐ 
கᾞᾷᾐᾰகைள ெவளியிᾌΆ ேபாேதா அ᾿லᾐ ஆராᾼᾲசியிᾹ ேபாேதா தᾱகளᾐ ெபயைரேயா 
அ᾿லᾐ அைடயாளᾱகைளேயா ெவளியிடமா᾵ேடாΆ எᾹபைதᾜΆ ெதாிவிᾷᾐᾰ 
ெகா῀கிேறாΆ. 
இᾸத ஆராᾼᾲசியி᾿ பᾱேகιபᾐ தᾱகᾦைடய விᾞᾺபᾷதிᾹ ேபாி᾿ தாᾹ இᾞᾰகிறᾐ. 
ேமᾤΆ நீᾱக῀ எᾸேநரᾙΆ இᾸத ஆராᾼᾲசியிᾢᾞᾷᾐ பிᾹவாᾱகலாΆ எᾹபைதᾜΆ 
ெதாிவிᾷᾐᾰ ெகா῀கிேறாΆ. 
இᾸத சிறᾺᾗᾺ பாிேசாதைனகளிᾹ ᾙᾊᾫகைள ஆராᾼᾲசியிᾹ ேபாᾐ அ᾿லᾐ 
ஆராᾼᾲசியிᾹ ᾙᾊவி᾿ தᾱகᾦᾰᾁ அறிவிᾺேபாΆ எᾹபைதᾜΆ ெதாிவிᾷᾐᾰ ெகா῀கிேறாΆ. 
 
ஆராᾼᾲசியாள᾽ ைகெயாᾺபΆ பᾱேகιபாள᾽ ைகெயாᾺபΆ 
 
 
ேததி: 
  
PATIENT CONSENT FORM 
Study detail                  :  CORRELATION OF CD4 CELL COUNT WITH CAROTID 
                                              CAROTID INTIMA MEDIA THICKNESS IN HIV PATIENTS                                      
Study centre                 :  INSTITUTE OF INTERNAL MEDICINE , Madras Medical     
  College and Rajiv Gandhi Government General Hospital     
Patient’s Name             :          
Patient’s age                 :                                       
Identification number  : 
Patient may check ( ) these boxes 
The details of the study have been provided to me in writing and explained to  
me in my own language                                                                                                                 ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason , without legal rights being affected.               ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf , the ethical committee and the regulatory authorities will not need my 
permission to look my health records , both in respect of current study and any 
further research that may be conducted in relation to it , even if I withdraw from 
the study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published , unless as  
required under the law. I agree not to restrict the use of any data or results that 
arise from this study.                                                                                                                     ❏ 
I agree to  take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff  I suffer from any deviation in my health or well being or any  
unexpected or unusual symptoms                                                                                                 ❏ 
I hereby consent to participate in this study                                                                                  ❏ 
 
I hereby give permission to undergo complete clinical examination , biochemical 
and radiological tests                                                                                                                     ❏ 
 
 
Signature of Investigator     Signature/thumb impression 
Study Investigator’s Name:   Patient’s Name and Address: 
DR. SIVA SHANMUGANATHAN V 
  
  
 	
  
ஆராᾼᾲசி தைலᾺᾗ: 
எᾲ.ஐ.வி ேநாயினா᾿ பாதிᾰகᾺப᾵ேடாாிᾹ இரᾷத நாளᾱகளி᾿ ஏιபᾌΆ அைடᾺபிιᾁΆ 
ெவ῀ைள இரᾷத அᾎᾰகᾦᾰᾁΆ இைடேய உ῀ள ெதாட᾽பிைன  பιறிய ஆராᾼᾲசி. 
ெபய᾽: ேததி: 
வயᾐ: உ῀ேநாயாளி எᾶ: 
பா᾿: ஆராᾼᾲசி ேச᾽ᾰைக எᾶ: 
 
இᾸத ஆராᾼᾲசியிᾹ விவரᾱகᾦΆ அதᾹ ேநாᾰகᾱகᾦΆ ᾙᾨைமயாக எனᾰᾁ 
ெதளிவாக விளᾰகᾺப᾵டᾐ. எனᾰᾁ விளᾰகᾺப᾵ட விஷயᾱகைள நாᾹ ᾗாிᾸᾐ ெகாᾶᾌ 
நாᾹ எனᾐ சΆமதᾷைத ெதாிவிᾰகிேறᾹ. 
இᾸத ஆராᾼᾲசியி᾿ ெவ῀ைள இரᾷத அᾎᾰகளிᾹ எᾶணிᾰைக மιᾠΆ கᾨᾷதி᾿ 
உ῀ள இரᾷத நாளᾱகளி᾿ ஏιபᾌΆ அைடᾺபிைன கᾶடறிᾜΆ ῄேகᾹ பாிேசாதைனகைளᾺ 
பιறிᾜΆ ஆராᾼᾲசியாள᾽ ᾂற ᾙᾨவᾐΆ விளᾱகᾺெபιேறᾹ. 
ேமιெகாᾶட பாிேசாதைனயிᾹ ேபாᾐ ஏιபடᾰᾂᾊய பிᾹவிைளᾫகைளᾜΆ 
ᾙᾨவᾐΆ உண᾽Ᾰᾐ இᾸத பாிேசாதைனᾰᾁ மனமார சΆமதிᾰகிேறᾹ. 
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MASTER CHART 
 
S.NO AGE SEX CD4 COUNT CIMT-R CIMT-L CIMT-MEAN ART DURATION
1 48 F 758 0.3 0.3 0.3 4 YEARS
2 45 F 554 0.5 0.5 0.5 3 YEARS
3 35 M 597 0.4 0.4 0.4 1 YEAR
4 32 M 322 0.5 0.6 0.55 7 YEARS
5 48 M 189 0.6 0.7 0.65 10 YEARS
6 54 M 1039 0.3 0.4 0.35 1 YEAR
7 49 F 134 0.6 0.6 0.6 2 YEARS
8 22 F 297 0.4 0.4 0.4 3 YEARS
9 34 F 642 0.5 0.5 0.5 2 YEARS
10 53 M 478 0.3 0.3 0.3 1 YEAR
11 37 F 609 0.6 0.5 0.55 3 YEARS
12 42 M 1508 0.2 0.3 0.25 1 YEAR
13 54 F 600 0.5 0.5 0.5 4 YEARS
14 47 M 710 0.5 0.6 0.55 2 YEARS
15 39 M 301 0.3 0.4 0.35 3 YEARS
16 47 F 681 0.4 0.4 0.4 4 YEARS
17 37 F 722 0.4 0.4 0.4 1 YEAR
18 38 F 556 0.3 0.3 0.3 3 YEARS
19 26 M 97 0.6 0.6 0.6 4 YEARS
20 52 F 199 0.8 0.7 0.75 9 YEARS
21 44 M 643 0.2 0.2 0.2 3 YEARS
22 34 M 721 0.4 0.4 0.4 5 YEARS
23 31 M 410 0.3 0.3 0.3 4 YEARS
24 24 F 627 0.3 0.3 0.3 2 YEARS
25 35 F 276 0.4 0.4 0.4 5 YEARS
26 52 F 357 0.3 0.3 0.3 8 YEARS
27 40 F 205 0.6 0.6 0.6 6 YEARS
28 26 M 112 0.6 0.7 0.65 3 YEARS
29 42 M 178 0.7 0.7 0.7 6 YEARS
30 32 M 711 0.3 0.3 0.3 5 YEARS
31 35 F 179 0.4 0.5 0.45 8 YEARS
32 43 M 399 0.2 0.2 0.2 9 YEARS
33 32 M 478 0.4 0.3 0.35 4 YEARS
34 37 M 744 0.3 0.3 0.3 3 YEARS
35 42 M 299 0.4 0.4 0.4 4 YEARS
36 32 F 312 0.5 0.5 0.5 4 YEARS
37 45 M 569 0.5 0.4 0.45 5 YEARS
38 54 M 101 0.9 0.9 0.9 6 YEARS
39 24 F 59 0.5 0.5 0.5 5 YEARS
40 51 F 531 0.3 0.3 0.3 8 YEARS
41 40 M 364 0.5 0.4 0.45 7 YEARS
42 63 M 295 0.6 0.5 0.55 5 YEARS
43 45 M 359 0.4 0.4 0.4 3 YEARS
44 43 F 410 0.5 0.4 0.45 6 YEARS
45 47 M 201 0.5 0.5 0.5 4 YEARS
46 39 F 653 0.2 0.2 0.2 4 YEARS
47 46 F 397 0.3 0.3 0.3 3 YEARS
48 54 F 356 0.4 0.4 0.4 3 YEARS
49 38 F 709 0.3 0.3 0.3 7 YEARS
50 32 F 412 0.4 0.4 0.4 4 YEARS
51 34 M 309 0.4 0.3 0.35 4 YEARS
52 41 M 505 0.5 0.5 0.5 5 YEARS
53 42 M 576 0.6 0.6 0.6 5 YEARS
54 33 M 704 0.3 0.4 0.35 4 YEARS
55 45 F 101 0.5 0.6 0.55 5 YEARS
56 47 F 623 0.4 0.4 0.4 6 YEARS
57 43 M 654 0.4 0.4 0.4 4 YEARS
58 32 F 744 0.3 0.3 0.3 3 YEARS
59 43 M 201 0.8 0.8 0.8 7 YEARS
60 46 M 622 0.7 0.7 0.7 6 YEARS
61 53 M 271 0.9 0.9 0.9 4 YEARS
62 37 F 179 0.6 0.6 0.6 7 YEARS
63 44 F 798 0.2 0.3 0.25 1 YEAR
64 44 F 123 0.7 0.7 0.7 8 YEARS
65 32 F 663 0.4 0.4 0.4 6 YEARS
66 42 M 390 0.4 0.4 0.4 2 YEARS
67 36 M 729 0.4 0.3 0.35 4 YEARS
68 24 M 376 0.2 0.2 0.2 3 YEARS
69 61 M 195 1 1.1 1.05 7 YEARS
70 38 M 456 0.5 0.5 0.5 1 YEAR
71 29 F 222 0.5 0.4 0.45 2 YEARS
72 49 F 548 0.4 0.5 0.45 3 YEARS
73 53 F 354 0.5 0.5 0.5 7 YEARS
74 27 M 503 0.3 0.3 0.3 4 YEARS
75 29 M 423 0.2 0.2 0.2 3 YEARS
76 41 F 551 0.3 0.3 0.3 3 YEARS
77 51 F 411 0.3 0.4 0.35 4 YEARS
78 54 M 468 0.4 0.4 0.4 3 YEARS
79 46 F 593 0.3 0.3 0.3 8 YEARS
80 37 F 190 0.5 0.5 0.5 5 YEARS
81 39 F 298 0.6 0.7 0.65 5 YEARS
82 45 F 447 0.5 0.5 0.5 7 YEARS
83 52 M 678 0.4 0.4 0.4 3 YEARS
84 48 M 883 0.3 0.3 0.3 3 YEARS
85 23 M 234 0.5 0.5 0.5 2 YEARS
86 26 M 354 0.2 0.2 0.2 5 YEARS
87 38 F 421 0.2 0.3 0.25 6 YEARS
88 57 F 567 0.3 0.3 0.3 3 YEARS
89 50 F 270 0.4 0.4 0.4 2 YEARS
90 47 M 378 0.4 0.5 0.45 1 YEAR
91 45 F 910 0.3 0.3 0.3 3 YEARS
92 39 M 856 0.3 0.3 0.3 3 YEARS
93 35 M 566 0.4 0.5 0.45 4 YEARS
94 43 M 678 0.5 0.5 0.5 6 YEARS
95 46 M 765 0.4 0.4 0.4 4 YEARS
96 39 M 973 0.5 0.4 0.45 5 YEARS
97 51 F 478 0.3 0.4 0.35 4 YEARS
98 43 M 417 0.4 0.4 0.4 1 YEAR
99 44 M 291 0.5 0.5 0.5 2 YEARS
100 37 M 358 0.5 0.5 0.5 5 YEARS
